新生血管性年龄相关性黄斑变性(nAMD)是发达国家50岁以上人群严重视力障碍的主要原因。玻璃体内注射抗血管内皮生长因子(VEGF)已成为治疗nAMD的标准治疗方法;然而,由于疾病的慢性性质和有限的药物半衰期,每月或每两个月给药代表显著的时间和成本负担。
■这篇综述总结了nAMD的创新疗法和给药方法。用于延长药物递送的新兴方法包括高摩尔浓度的抗VEGF药物,玻璃体内缓释装置,用于玻璃体内递送的储库,和基因治疗生物工厂。除了VEGF-A,靶向抑制VEGF-C和D的疗法,血管生成素-2(Ang-2)/Tie-2通路,酪氨酸激酶,和整合素进行了综述。
■nAMD不断发展的治疗前景正在迅速扩展我们的工具包,以进行有效和持久的治疗。最近FDA批准的faricimab(Vabysmo)和高剂量阿柏西普(EyleaHD)用于nAMD,其注射间隔可能延长至四个月,这对患者和提供者都是有希望的发展。进一步研究和创新,包括新的递送技术和药理靶点,对于验证开发治疗方法的有效性和表征现实世界的结果是必要的。证明在扩大处理耐久性的承诺。
UNASSIGNED: Neovascular age-related macular degeneration (nAMD) represents a leading cause of severe visual impairment in individuals over 50 years of age in developed nations. Intravitreal anti-vascular endothelial growth factor (VEGF) injections have become the standard of care for treating nAMD; however, monthly or bimonthly dosing represents significant time and cost burden due to the disease\'s chronic nature and limited medication half-life.
UNASSIGNED: This review summarizes innovative therapeutics and delivery methods for nAMD. Emerging methods for extended drug delivery include high molar concentration anti-VEGF drugs, intravitreal sustained release devices, reservoirs for intravitreal delivery, and gene therapy biofactories. In addition to VEGF-A, therapies targeting inhibition of VEGF-C and D, the angiopoetin-2 (Ang-2)/Tie-2 pathway, tyrosine kinases, and integrins are reviewed.
UNASSIGNED: The evolving therapeutic landscape of nAMD is rapidly expanding our toolkit for effective and durable treatment. Recent FDA approvals of faricimab (Vabysmo) and high dose aflibercept (Eylea HD) for nAMD with potential extension of injection intervals up to four months have been promising developments for patients and providers alike. Further research and innovation, including novel delivery techniques and pharmacologic targets, is necessary to validate the efficacy of developing therapeutics and characterize real-world outcomes. demonstrating promise in expanding treatment durability.